8-KOther Events

AMGEN INC 8-K Report (Mar 1, 2002)

Filed March 1, 2002For Securities:AMGN

Summary

Amgen Inc. (AMGN) filed an 8-K report on March 1, 2002, disclosing a significant financing transaction. On March 1, 2002, the company successfully issued $3.95 billion in aggregate principal face amount of 30-year zero-coupon senior notes, which are convertible into Amgen common stock. The gross proceeds generated from this offering amounted to approximately $2.8 billion. These substantial funds are earmarked for strategic corporate initiatives. A significant portion, approximately $650 million, will be used to repurchase the company's common stock concurrently with the note issuance. The remaining proceeds are allocated for general corporate purposes, including potential acquisitions, further share repurchases, capital expenditures, and working capital needs. This move signals Amgen's proactive approach to capital management and its intention to enhance shareholder value through strategic investments and capital allocation.

Key Highlights

  • 1Amgen Inc. issued $3.95 billion in 30-year zero-coupon senior convertible notes on March 1, 2002.
  • 2Gross proceeds from the note issuance were approximately $2.8 billion.
  • 3The notes are convertible into shares of Amgen common stock.
  • 4Proceeds will fund a $650 million share repurchase program initiated concurrently with the note issuance.
  • 5Remaining funds are designated for general corporate purposes, including acquisitions, further share repurchases, capital expenditures, and working capital.
  • 6The filing indicates a proactive capital management strategy by Amgen.
  • 7The transaction was structured with involvement from financial institutions like Merrill Lynch.

Frequently Asked Questions

The primary purpose of this 8-K filing was to disclose Amgen Inc.'s issuance of $3.95 billion in 30-year zero-coupon senior convertible notes on March 1, 2002, and the intended use of the approximately $2.8 billion in gross proceeds.

Amgen expects to use approximately $650 million of the proceeds to repurchase its common stock concurrently with the note issuance. The remaining funds are allocated for general corporate purposes, which include potential acquisitions, additional share repurchases, capital expenditures, and working capital.

The notes are 30-year zero-coupon senior notes with an aggregate principal face amount of $3.95 billion. They are also convertible into shares of Amgen common stock.

The simultaneous repurchase of approximately $650 million of common stock suggests that Amgen is aiming to offset the dilutive effect of potential future conversions of the notes or is actively managing its capital structure by returning capital to shareholders.